Endologix Inc. (NASDAQ:ELGX)’s share price fell 2.2% during trading on Monday . The stock traded as low as $13.88 and last traded at $13.92, with a volume of 508,829 shares changing hands. The stock had previously closed at $14.24.

Several research firms have commented on ELGX. Canaccord Genuity reissued a “buy” rating on shares of Endologix in a report on Tuesday. BMO Capital Markets raised shares of Endologix from a “market perform” rating to an “outperform” rating and raised their target price for the company from $11.50 to $16.00 in a report on Thursday, July 7th. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 target price (up from $15.00) on shares of Endologix in a report on Wednesday, July 6th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $15.00 target price on shares of Endologix in a report on Monday, June 13th. Finally, Royal Bank Of Canada lifted their price target on shares of Endologix from $15.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Endologix presently has a consensus rating of “Buy” and an average price target of $14.55.

The company has a 50 day moving average of $12.76 and a 200-day moving average of $10.10. The firm’s market cap is $1.13 billion.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. During the same period in the previous year, the company posted ($0.14) earnings per share. The business earned $42.40 million during the quarter, compared to analysts’ expectations of $38.78 million. The firm’s revenue was up 15.5% compared to the same quarter last year. Analysts predict that Endologix Inc. will post ($0.79) earnings per share for the current year.

In other Endologix news, Director Gregory D. Waller sold 7,800 shares of the business’s stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $12.86, for a total transaction of $100,308.00. Following the transaction, the director now owns 27,728 shares in the company, valued at approximately $356,582.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John D. Mcdermott sold 6,116 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $12.55, for a total value of $76,755.80. Following the transaction, the chief executive officer now owns 663,624 shares in the company, valued at approximately $8,328,481.20. The disclosure for this sale can be found here.

A number of institutional investors have added to or reduced their stakes in the company. Tamarack Advisers LP acquired a new position in Endologix during the fourth quarter valued at about $44,303,000. California State Teachers Retirement System boosted its position in Endologix by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 124,973 shares of the company’s stock valued at $1,237,000 after buying an additional 2,243 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in Endologix by 134.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,020 shares of the company’s stock valued at $1,485,000 after buying an additional 85,920 shares during the last quarter.

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.